Results. For CRISS a Delphi process combined with expert review resulted in 11 candidate domains for inclusion in a core set of outcomes for SSc clinical trials. These domains are soluble biomarkers, cardiac, digital ulcers, gastro-intestinal, global health, health related quality of life and function, musculoskeletal, pulmonary, Raynaud's, renal and skin. Tools within domains were also agreed upon.
EPOSS concentrated on one aspect of the disease, PAH. Using a Delphi process, the following domains were judged as most appropriate for randomised controlled trials in PAH-SSC: lung vascular/pulmonary arterial pressure, cardiac function, exercise testing; severity of dyspnea, discontinuation of treatment; quality of life/activities of daily living; global state; and survival. Possible useful tools within each domain were also agreed upon.
Patient derived, Physician derived and objective measures of response will be included and combined with the idea that each reflects different aspects of PAH(EPOSS) and overall disease (CRISS), although this may not prove true and can be considered for separation if statistically and clinically valid to do so.
Plans. In both cases, prospective studies to include measurement of all domains and tools are required and are being undertaken to define appropriate combined measures of response
Conclusion. An overall combined measures of response in systemic sclerosis (CRISS) and a combined measure of response for PAH-SSC (EPOSS) are being developed through the OMERACT process. Significant progress has been made using the Delphi process and literature review for both indices and prospective data are being collected. Together with the CRISS effort (see below), the EPOSS work will develop a set of domains and tools specific for PAH-SSc. These are, in fact, complementary rather than combined efforts, although many of the same techniques and analyses apply to both the CRISS and EPOSS, thus justifying close, cooperative and synergistic efforts.
INTRODUCTION
There has been substantial progress over the past decade in the development and validation of outcome measures and refinement of trial methodology in SSc 4, 5, 6 . This progress has been paralleled by an increased understanding of the pathogenesis of SSc and development of targeted therapies 7, 8, 9 . The modified Rodnan skin score, a measure of skin thickness, has been used as the primary outcome measure in clinical trials of diffuse cutaneous SSc (called diffuse SSc or dcSSc from here on) 10, 11 . However, the complexity and heterogeneity of the disease mandates a composite response measure that will capture differing organ involvements and patient-reported outcomes. Wellvalidated, widely accepted combined response indices are more likely to be responsive to change than individual measures 12, 13 , will facilitate drug development and improve assessment of efficacy of therapeutic agents 12, 14 .
A CRISS for use in clinical trials of patients with diffuse SSc could facilitate the interpretation of results from clinical trials, similar to the American College of Rheumatology (ACR) response criteria and the Disease Activity Score definitions for rheumatoid arthritis. Rather than using numerous outcomes that vary from trial to trial, a core set of outcomes will produce a single efficacy measure.
This article will outline the progress and plans for the EPOSS and CRISS initiatives.
Results and Plans

A. EPOSS (Expert Panel on Outcome Measures in PAH related to Systemic Sclerosis)
Progress to Date:
The EPOSS group first published an article defining the need for improved outcome measures in pulmonary arterial hypertension related to systemic sclerosis (PAH-SSC) 15 .
Using a Delphi process, a series of domains and tools were developed which might be used as alternative endpoints to the use of the right heart catheterisation (RHC)
to define PAH-SSc, as repeated RHC are difficult to accomplish in clinical trials. (Table 1 ).
An additional analysis examined the differences in responses between pulmonologists and cardiologists compared to rheumatologists 17 . In general, it was found that rheumatologists favoured patient-derived questionnaires more frequently than cardiologists/pulmonologists while the latter favoured specific pulmonary related measures of response, but that a combination of results encompassing both groups' assessments are required for full description and measurement of PSH-SSc
Preparatory to a prospective study and/or use of existing data to validate the domains and tools outlined above, an in depth structured literature review has been undertaken for echocardiography and for the six minute walk test (both accepted as posters and presented at the 2008 EULAR meeting). The structured literature review will show which parts of the selected outcome measures have already been sufficiently validated in PAH-SSc according to the OMERACT filter to require no more research.
More importantly, it will define those measures that need further validation before those measures can be used to assess PAH-SSc.
Plans:
For the EPOSS effort, we are presently: 1. Completing the systematic literature review on core set outcomes defined by the Delphi study 2. Planning to validate the domains and tools as chosen through the Delphi exercise sub-analysis on PAH-SSc patients from the placebo arms of these studies will be performed and we are attempting to get these data at present.
Developing a patient Delphi exercise
From the patients' perspective, changes in functional ability may be more distressing and debilitating than changes in objective measures of disease that are often used by physicians. However, there is insufficient information regarding which domains may be most important to patients, because many outcome measures used in PAH/SSc report either generic QOL, or single domains (e.g., physical function) or are not measured (e.g., fatigue).
(a) We will evaluate patients' assessment of the disease and symptom burden in PH/SSc using patient-centered qualitative methods. This adds an important component to the core set defined by physicians outlined above. We will conduct focus groups and interviews of PH/SSc patients in order to determine patients' perceptions of disease activity, disability, and HRQOL and to identify areas most distressful and concerning to patients.
4. The physician derived and objective measures of response will be developed separately from the patient derived measures. When completed, these two approaches to PAH/SSc will be examined in combination and separately to ascertain which approach is more sensitive to change in clinical trials, as they probably describe somewhat different aspects of PAH/SSc, thus improving the combined discriminating ability of a combined measure. On the other hand, there is no reason to insist on their combination in all circumstances and they may/should be used separately when it is appropriate.
Further, if their combination does not enhance the discriminating ability of the combined measure, or if one or the other, by themselves, are better discriminators of response, this , too, will be ascertained.
B. CRISS (Combined Response Index for Systemic Sclerosis)
Progress to date:
The first step in developing a Combined Response Index in Systemic Sclerosis (CRISS) was taken by conducting a structured Delphi exercise with participation of the Scleroderma Clinical Trial Consortium membership, to develop a provisional core set of items for clinical trials 18 . In this exercise, 50 investigators provided 212 unique items for 11 domains in a one-year clinical trial of SSc patients. In this trial 92% of the original investigators responded in the second round and rated 177 items. Nominal group technique examined these data for consistency, redundancy, feasibility and validity, judging 31 of the items from the 11 domains to be appropriate for inclusion in a one-year multicentre clinical trial.
Thereafter, in a modified third round, the investigators ranked 30 of the 31 items as acceptable for inclusion in the course. The final domains chosen were (need these from the article) ( Table 2 ). An additional 14 items were included in a research agenda. (Table 3 ) Dan: we will need ARD approval for these tables if Unfortunately, the 635-patient data-set lacks a number of the core set items chosen in the recent Delphi exercise, making that data-set unsuitable to completely test the proposed CRISS. Therefore, we are assessing all of the proposed core set items in a 1-year longitudinal observational study (see above)
and will then employ a prospective, data-driven, consensus building technique to develop and quantitatively evaluate candidate definitions for a CRISS that will capture different organ involvements and patient-reported outcomes.
For the CRISS effort, we are presently: b) We will assess the reliability, validity and responsiveness of the core set items from the real patient data collected in the 1-year observational study.
c) We will revise and define a final core set based on the results obtained from Specific Aim 1b.
d) The same considerations as for EPOSS will be true for the patient-derived aspects of the CRISS, as the potential tools in the CRISS include a number of patient-derived outcomes (e.g., SF-36, HAQ-DI, pain, global evaluations, and dyspnea). These will be considered in the same manner as for EPOSS, although for the present no separate evaluation by patients is planned. We are planning a sample size of 200 patients to be able to select patient profiles plus anticipated dropouts c) We will use the ratings of the key-opinion leaders as the gold standard to estimate validity characteristics, such as sensitivity and specificity, we will compare each using area under the curve and receiver operating characteristics analyses.
d) We will select a definition of CRISS for use in clinical trials in diffuse SSc that has high statistical discriminatory power and is most credible (highest face validity).
In SSc, the multiple organ system involvements can be either reversible or irreversible and the measures to separate these two aspects of SSc are not available. Rather the process of choosing the tools within the domains will be utilised to choose tools which are most sensitive to change. This, by implication, assumes those tools reflect reversible aspects of SSc, although this is clearly an empiric rather than physiologic or pathologically based decision By grouping the patient derived measures, it may also be possible to find a patient oriented portion of the CRISS, which can be used separately or within the complete CRISS.
However, should the patient derived measures prove to be an integral and required portion of the CRISS, when considering sensitivity to change and clinical relevance (as seen in American College of Rheumatology criteria for rheumatoid arthritis and juvenile idopathic arthritis), this finding will be specifically addressed when the final version of the CRISS has been completed.
CONCLUSION
An overall combined measures of response in systemic sclerosis (CRISS) and a combined measure of response for PAH-SSc (EPOSS) are being developed through the OMERACT process. Significant progress has been made using the Delphi process and literature review for both indices and prospective data are being collected. Standardised central reading mechanism strongly encouraged, * if relevant to the study,
